RSS   Newsletter   Contact   Advertise with us

WuXi Biologics and Bayer enter into acquisition agreement

Share on Twitter Share on LinkedIn
Christian Fernsby ▼ | January 16, 2020
WuXi Biologics and Bayer jointly announced an acquisition agreement that WuXi Biologics Germany will take over the operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building.
WuXi Biologics
Acquisition   WuXi Biologics
Based on a manufacturing agreement to be negotiated, the plant would be operated by WuXi Biologics and serve as a back-up site for the final product manufacturing of Kovaltry™, an antihemophilic factor (recombinant).

Topics: WuXi Biologics Bayer acquisition

The transaction is expected to be concluded in the coming months subject to the satisfaction of customary closing conditions.

Financial details were not disclosed.


 

MORE INSIDE POST